Brief: Cosmo Pharmaceuticals Says Termination Of Agreement For Rifamycin Sv Mmx® With Dr. Falk Pharma
04/09/2023 05:51
Sept 4 (Reuters) - Cosmo Pharmaceuticals NV COPN.S :
* TERMINATION OF AGREEMENT FOR RIFAMYCIN SV MMX® WITH DR.
FALK
PHARMA
* TERMINATION BY MUTUAL AGREEMENT OF LICENSE WITH DR. FALK
PHARMA
FOR RIFAMYCIN SV MMX IN EU AND SELECTIVE COUNTRIES
Source text for Eikon: ID:nEQ8rjy3la
Further company coverage: COPN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cosmo NV
See all newsFocus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance
Brief: Cosmo Pharmaceuticals H1 EPS EUR -0.279
Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study
Europe Research Roundup: Airbus ,Bechtle, Salzgitter